Stephen B Brugger Net Worth

The estimated Net Worth of Stephen B Brugger is at least $16.2 millió dollars as of 28 October 2010. Stephen Brugger owns over 55,730 units of Momenta Pharmaceuticals stock worth over $13,902,897 and over the last 20 years Stephen sold MNTA stock worth over $2,315,373.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephen Brugger MNTA stock SEC Form 4 insiders trading

Stephen has made over 15 trades of the Momenta Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Stephen exercised 55,730 units of MNTA stock worth $12,818 on 28 October 2010.

The largest trade Stephen's ever made was exercising 82,510 units of Momenta Pharmaceuticals stock on 6 September 2005 worth over $18,977. On average, Stephen trades about 11,683 units every 85 days since 2005. As of 28 October 2010 Stephen still owns at least 264,918 units of Momenta Pharmaceuticals stock.

You can see the complete history of Stephen Brugger stock trades at the bottom of the page.

What's Stephen Brugger's mailing address?

Stephen's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Momenta Pharmaceuticals

Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler és Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.

What does Momenta Pharmaceuticals do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Complete history of Stephen Brugger stock trades at Momenta Pharmaceuticals

Momenta Pharmaceuticals executives and stock owners

Momenta Pharmaceuticals executives and other stock owners filed with the SEC include:

• Donna Roy Grogan,
  Director
• Jose Carlos Gutierrez Ramos,
  Director
• Santiago Arroyo,
  SVP, Chief Medical Officer
• Craig A Wheeler,
  President & CEO
• Corey N. Fishman,
  Director
• Marsha Fanucci,
  Director
• James R Sulat,
  Director
• Bruce Leicher,
  SVP & General Counsel
• Matthew P. Ottmer,
  Chief Operating Officer
• Richard P Shea,
  VP, Chief Financial Officer
• Georges Gemayel,
  Director
• Thomas P Koestler,
  Director
• Steven C Gilman,
  Director
• Bruce Downey,
  Director
• Elizabeth Stoner,
  Director
• Scott M Storer,
  SVP, CFO
• James M. Roach,
  Senior VP, Development and Chi
• Michelle Robertson,
  Chief Financial Officer
• Anthony M. Manning,
  Chief Scientific Officer
• Jo Ann Beltramello,
  Chief HR and Inf. Officer
• Alejandra Carvajal,
  Chief Legal Officer
• Ian Fier,
  Chief Mfg and Program Officer
• Young Kwon,
  Chief Financial & Bus. Officer
• Peter Barrett,
  Director
• Peter Barton Hutt,
  Director
• Paul D Goldenheim,
  Director
• Stephen B Brugger,
  VP, Strategic Prod Devl.
• John L Zabriskie,
  Director
• Ram Sasisekharan,
  Director
• Venture Management Co Iii L...,
  
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Bennett M Shapiro,
  Director
• Stephen T Reeders,
  Director
• International Life Sciences...,
  10% owner
• Ganesh Venkataraman,
  VP, Technology
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Michael Franken,
  President, Biosimilars Busines
• Robert Langer,
  Director
• Carron Shmerling Lisa,
  V.P., Legal Affairs
• John E Bishop,
  VP Pharma Sciences & Manufact
• Susan K Whoriskey,
  VP, Licensing and Bus. Develop
• Alan L Crane,
  President and CEO
• Venture Fund V Lpatlas Vent...,
  
• John K Clarke,
  Director
• Jane F Barlow,
  Director
• Agnieszka Cieplinska,
  Chief Accounting Officer (PAO)